Fiche d'information compilée à partir de PubMed
Cette fiche a été compilée à partir de résumés PubMed (NIH) avec l'assistance d'une IA. Chaque affirmation factuelle est citée par un article PubMed réel (voir la liste des sources). Elle n'a pas encore été révisée par un humain — confirmez auprès d'un professionnel de santé avant utilisation.
Compilé à partir de 2 articles PubMed · modèle : gemma4:31b
Résumé
Habb-e-asgandh, a polyherbal formulation containing Ashwagandha, has demonstrated anti-tumorigenic and anti-proliferative effects in multiple myeloma cell lines [PMID:38019228, PMID:36444574].
Contexte
Habb-e-asgandh is a Unani herbal drug formulation used as an adjuvant therapy in the treatment of multiple myeloma [PMID:38019228].
Mécanisme d'action
Habb-e-asgandh induces apoptosis through mitochondrial dysfunction and suppresses cell proliferation by reducing proliferating cell nuclear antigen (PCNA) activity in multiple myeloma cells [PMID:36444574]. It also exhibits multi-strategic cytotoxic effects and influences anti-inflammatory (TNF-alpha, IL6) and anti-angiogenic (VEGF, Ang-2) markers [PMID:38019228].
Preuves cliniques
Preuve DMultiple Myeloma (U266 cells)
Habb-e-asgandh exhibits adjunctive antitumor efficacy and cytotoxic effects, either alone or in combination with lenalidomide [PMID:38019228].
Preuve DMultiple Myeloma (RPMI8226 cells)
Habb-e-asgandh suppresses cell proliferation and induces apoptosis via mitochondrial dysfunction; LD30 and LD50 doses were determined as 0.3mg/ml and 0.5mg/ml respectively [PMID:36444574].
Interactions médicamenteuses
Habb-e-asgandh has been studied in combination with the standard drug lenalidomide to evaluate efficacy against drug relapse and resistance in myeloma cells [PMID:38019228, PMID:36444574].
Synthèse des preuves
The current evidence is limited to in vitro experimental studies (cell lines) demonstrating anti-cancer properties of a specific polyherbal formulation; no human clinical trials are provided.
Sources PubMed
- 1.PMID: 38019228 (2023) — A Polyherbal Ashwagandha Formulation Exhibits Adjunctive Antitumor Efficacy Against U266 Myeloma Cells by Multi-Strategic Cytotoxic Effects: An Experimental Approach. · Asian Pacific journal of cancer prevention : APJCP
- 2.PMID: 36444574 (2022) — Habb-e-Asgandh Suppresses Cell Proliferation and Induces Apoptosis through Mitochondria Dysfunction in Multiple Myeloma Cells (RPMI8226). · Asian Pacific journal of cancer prevention : APJCP